Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments for global rights to a novel immune checkpoint inhibitor.
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22
![](https://ibf.fund/wp-content/uploads/2019/01/logoBiond.png)